Extended Data Fig. 9: Single-cell RNA-Seq and immunofluorescence of Vortioxetine-treated glioblastoma patient cells. | Nature Medicine

Extended Data Fig. 9: Single-cell RNA-Seq and immunofluorescence of Vortioxetine-treated glioblastoma patient cells.

From: High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Extended Data Fig. 9

a, UMAP projection of 1736 single cells from patient sample P024 upon 3 h of treatment with Vortioxetine (VORT; n = 577 cells; purple; 20 µM) or DMSO vehicle control DMSO; n = 1159 cells; grey). b, Expression levels of the top five marker genes expressed in more than 10% of cells per scRNA-Seq cluster (columns) in Extended Data Fig. 9a. Circle sizes scale with the percent of cells within each cluster expressing each gene. Color scale represents log10(mean+0.1) expression. c, Cell cycle inference for each cluster in Extended Data Fig. 9b using Seurat version 4.3.080. d, Percent of CD45+ immune or NES+ glioblastoma cells expressing AP-1 factors measured by immunofluorescence in glioblastoma patient samples (n = 11 patients) 24 h after DMSO control or Vortioxetine-treatment ex vivo (10 and 20 µM). Patient-matched paired two-tailed t-test (compared to DMSO control) with FDR-adjusted P-values. Boxplots show 25th–75th percentiles with a line at the median; whiskers extend to 1.5 times the interquartile range.

Source data

Back to article page